Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
W0180 Monotherapy and Combination with Pembrolizumab in Advanced Solid Tumors
NCT04564417Phase 1Terminated
- Sponsor
- Pierre Fabre Laboratories
- Start
- Sep 2020
- Primary completion
- Dec 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of W0180 in solid tumor (3 arms), sponsored by Pierre Fabre Laboratories. Primary endpoint: Dose-limiting toxicities. Started Sep 2020; status: terminated.
02
Drugs
W0180
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04564417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04564417.